464 related articles for article (PubMed ID: 27483368)
1. Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.
Hayes JF; Marston L; Walters K; Geddes JR; King M; Osborn DP
PLoS Med; 2016 Aug; 13(8):e1002058. PubMed ID: 27483368
[TBL] [Abstract][Full Text] [Related]
2. Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study.
Hayes JF; Pitman A; Marston L; Walters K; Geddes JR; King M; Osborn DP
JAMA Psychiatry; 2016 Jun; 73(6):630-7. PubMed ID: 27167638
[TBL] [Abstract][Full Text] [Related]
3. Mortality risk and mood stabilizers in bipolar disorder: a propensity-score-weighted population-based cohort study in 2002-2018.
Chan JKN; Wong CSM; Fang CZ; Hung SC; Lo HKY; Chang WC
Epidemiol Psychiatr Sci; 2024 May; 33():e31. PubMed ID: 38779809
[TBL] [Abstract][Full Text] [Related]
4. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.
Bridle C; Palmer S; Bagnall AM; Darba J; Duffy S; Sculpher M; Riemsma R
Health Technol Assess; 2004 May; 8(19):iii-iv, 1-187. PubMed ID: 15147609
[TBL] [Abstract][Full Text] [Related]
5. Bipolar Disorder and Outcomes of Monotherapy with Lithium, Valproate, Quetiapine, Olanzapine, Venlafaxine, and Citalopram.
Bohlken J; Riedel-Heller S; Bauer M; Kostev K
Pharmacopsychiatry; 2021 May; 54(3):126-130. PubMed ID: 33494115
[TBL] [Abstract][Full Text] [Related]
6. Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations.
Wingård L; Bodén R; Brandt L; Tiihonen J; Tanskanen A; Kieler H; Andersen M; Reutfors J
J Affect Disord; 2017 Aug; 217():16-23. PubMed ID: 28364619
[TBL] [Abstract][Full Text] [Related]
7. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.
Woodward TC; Tafesse E; Quon P; Lazarus A
Pharmacoeconomics; 2010; 28(9):751-64. PubMed ID: 20623994
[TBL] [Abstract][Full Text] [Related]
9. Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records.
Hayes JF; Marston L; Walters K; Geddes JR; King M; Osborn DP
World Psychiatry; 2016 Feb; 15(1):53-8. PubMed ID: 26833609
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis.
Fajutrao L; Paulsson B; Liu S; Locklear J
Clin Ther; 2009 Jun; 31 Pt 1():1456-68. PubMed ID: 19698903
[TBL] [Abstract][Full Text] [Related]
11. Lithium for acute mania.
McKnight RF; de La Motte de Broöns de Vauvert SJGN; Chesney E; Amit BH; Geddes J; Cipriani A
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD004048. PubMed ID: 31152444
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
Lee HB; Yoon BH; Kwon YJ; Woo YS; Lee JG; Kim MD; Bahk WM
Clin Drug Investig; 2013 Oct; 33(10):743-53. PubMed ID: 23990283
[TBL] [Abstract][Full Text] [Related]
13. Treatment of bipolar depression: making sensible decisions.
Citrome L
CNS Spectr; 2014 Dec; 19 Suppl 1():4-11; quiz 1-3, 12. PubMed ID: 25407667
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine in long-term treatment for bipolar disorder.
Cipriani A; Rendell JM; Geddes J
Cochrane Database Syst Rev; 2009 Jan; (1):CD004367. PubMed ID: 19160237
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.
Soares-Weiser K; Bravo Vergel Y; Beynon S; Dunn G; Barbieri M; Duffy S; Geddes J; Gilbody S; Palmer S; Woolacott N
Health Technol Assess; 2007 Oct; 11(39):iii-iv, ix-206. PubMed ID: 17903393
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials.
Smith LA; Cornelius V; Warnock A; Bell A; Young AH
Bipolar Disord; 2007 Jun; 9(4):394-412. PubMed ID: 17547586
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological prevention of mood episodes in women with bipolar disorder during the perinatal period: A systematic review of current literature.
Uguz F
Asian J Psychiatr; 2020 Aug; 52():102145. PubMed ID: 32516746
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Treatment of Bipolar Disorder with Valproate: Updated Systematic Review and Meta-analyses.
Yee CS; Vázquez GH; Hawken ER; Biorac A; Tondo L; Baldessarini RJ
Harv Rev Psychiatry; 2021 May-Jun 01; 29(3):188-195. PubMed ID: 33795581
[TBL] [Abstract][Full Text] [Related]
19. Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine.
Osborn D; Marston L; Nazareth I; King MB; Petersen I; Walters K
Schizophr Res; 2017 May; 183():116-123. PubMed ID: 27884434
[TBL] [Abstract][Full Text] [Related]
20. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T; Ikuta T; Matsuda Y; Sakuma K; Okuya M; Mishima K; Iwata N
Mol Psychiatry; 2021 Aug; 26(8):4146-4157. PubMed ID: 33177610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
